Moderna had its Relative Strength (RS) Rating upgraded from 88 to 91 Wednesday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This unique rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an 80 or better RS Rating at the beginning of a new run.
Looking For Winning Stocks? Try This Simple Routine
Moderna is working on a cup without handle with a 197.54 buy point. The stock has cleared key moving averages, now we need to see if the stock can clear the breakout price in heavy volume.
Moderna reported negative growth for both the top and bottom lines last quarter.
The company holds the No. 125 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Genmab ADR and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
